WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

( An ISO 9001:2015 Certified International Journal )

An International Peer Review Journal for Medical Science and Pharma Professionals

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

World Journal of Advance Healthcare Research (WJAHR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , Cosmos Impact Factor , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , IFSIJ Measure of Journal Quality , Scientific Journal Impact Factor (SJIF) , International Scientific Indexing, UAE (ISI) (Under Process) , International Impact Factor Services (IIFS) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Academia , Scope Database , 

ISSN 2457-0400

Impact Factor  :  6.711

News & Updation

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in WJAHR coming Issue.

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • 6th International Conference on Human and Soci

    Venue:FCT Education Resource Center, Abuja- Nigeria                                        September 22-24, 2019

  • .

    6th INTERNATIONAL CONFERENCE ON EDUCATIONAL TECHNOLOGY AND CURRICULUM STUDIES(ICETC2019) 

     

    Venue: FCT Education Resource Center, Abuja-Nigeria

    September 22-24, 2019

  • New Issue Published

    Its Our pleasure to inform you that, WJAHR May 2024 Issue has been Published, Kindly check it on https://www.wjahr.com/home/current_issues

  • WJAHR: New Impact Factor

    WJAHR Impact Factor has been Increased to 6.711 for Year 2024.

  • WJAHR: MAY ISSUE PUBLISHED

    MAY 2024 Issue has been successfully launched on 1 MAY 2024.

Best Paper Awards

World Journal of Advance Healthcare Research (WJAHR)Honored the authors with best paper award, monthly based on the innovation of research work. Best paper will be selected by our expert panel.

Best Article of current issue

Download Article : Click here

Indexing

  Indexing

  • Google Scholar
  • Index Copernicus
  • SOCOLAR, China
  • Research Bible, Fuchu, Tokyo. JAPAN
  • Cosmos Impact Factor
  • Scientific Indexing Services (SIS)
  • UDLedge Science Citation Index
  • International Impact Factor Services
  • International Society for Research Activity (ISRA) Journal Impact Factor (JIF)
  • IFSIJ Measure of Journal Quality
  • Scientific Journal Impact Factor (SJIF)
  • International Scientific Indexing, UAE (ISI) (Under Process)
  • International Impact Factor Services (IIFS)
  • Web of Science Group (Under Process)
  • Directory of Research Journals Indexing
  • Scholar Article Journal Index (SAJI)
  • International Scientific Indexing ( ISI )
  • Academia
  • Scope Database

Abstract

AN OBSERVATIONAL STUDY ON SAFETY AND TOLERABILITY OF HIGH INTENSITY ATORVASTATIN IN CARDIOVASCULAR DISEASES

*Dasari Pavani, Bollam Prathyusha and Goulikar Sai Nishanth

ABSTRACT

Objective: The main objective of the study is to assess the safety and tolerability of high intensity atorvastatin in various cardiovascular diseases. Methodology: A prospecive observational study was conducted in the cardiology department (in patient) of a tertiary care hospital. The data was collected from the in-patient department after considering inclusion and exclusion criteria for a period of 6 months and a total of 120 patients were analyzed with data collection form by interviewing the patient’s about the socio -demographic questionnaire , for every 3 months the patient’s blood samples are collected to observe lipid values. Statistical tools like Chi-Square test and T-test were applied to the data by using SPSS software. Result: Among 120 patients, males are more predominant than females. Patient’s between the age group of 40 and 60 years are more prone to CVD. According to our data, 12.5% of patients are smokers, 30% are alcoholics and 12.5% patients are both alcoholics and smokers 25% of patients had a family history of HTN, 10 % of patients had a family history of DM and Heart disease and 7.5% of patients had a family history of Hypertension with Heart disease, 7.5% 0f patients had a family history of Hypertension with DM. Among 120 patients, 72 (60%) patients had a past history of Hypertension and DM. Among 120 patients, 25% of patients have IWMI, 25% of patients have AWMI, 12.5% of patients have NSTEMI, 2.5% patients have RHD, 15% patients have AIS, 10% patients have TIA, 10% patients have unstable angina. Among these patients, patients with IWMI(30) AND AWMI(30)were more common.40mgdose has been given to 54(45%) patients and 80mg dose has been given to 66(55%) patients. Conclusion: High intensity atorvastatin therapy was given for a period of 6 months in120 patients. High intensity atorvastatin is generally well tolerated in adults in both the 40mg and 80mg doses who are diagnosed with various types of CVD. The ADR of atorvastatin are well managed and are not severe and no one has been withdrawn from the therapy. The overall survival rate of the therapy is 100%. Thus, high intensity atorvastatin is safe and well tolerated.

[Full Text Article] [Download Certificate]